News | Left Atrial Appendage (LAA) Occluders | October 20, 2016

SentreHeart Announces Closing of $35 Million Funding Round for aMAZE Trial

Trial will evaluate the Lariat Suture Delivery Device as adjunctive treatment to ablation in patients with persistent or longstanding persistent atrial fibrillation

SentreHeart, Lariat Suture Delivery Device, financing round, aMAZE Trial

October 20, 2016 — SentreHeart Inc. announced in late September the closing of a $35 million Series D round of financing. Deerfield Management Company, a healthcare investment firm, led the financing, which included participation from SentreHeart’s existing investors U.S. Venture Partners, Prospect Ventures, Vivo Capital and Decheng Capital.

The proceeds will be utilized to complete the aMAZE (alternative-MAZE) randomized, pivotal clinical trial evaluating the use of the Lariat device for closure of the left atrial appendage (LAA) as an adjunctive treatment to ablation in patients with persistent or longstanding persistent atrial fibrillation (AFib). Deerfield Partner Ted Huber will join SentreHEART’s Board of Directors.

Recent studies have demonstrated that the Lariat device not only closes the LAA mechanicallyi, but can also isolate electrical activity within the LAAii, a known contributor for AFibiii. The objective of the aMAZE Trial is to demonstrate that Lariat for LAA closure, plus a pulmonary vein isolation (PVI) ablation, will lead to a reduced incidence of recurrent AFib compared to PVI alone, with a high safety profile.

The Lariat Suture Delivery Device is indicated for suture placement and knot tying in surgical procedures where soft tissues are being approximated and/or ligated with a pre-tied polyester suture. SentreHeart received U.S. Food and Drug Administration (FDA) 510(k) clearances for the device in 2006, 2009 and 2014. It also has CE Mark approval in Europe.

For more information: www.amazetrial.com

 

i Bartus K, et al. Percutaneous Left Atrial Appendage Suture Ligation Using the LARIAT Device in Patients with Atrial Fibrillation. J Am Coll Cardiol 2013 Jul 9;62(2):108-18.

ii Han FT, et al. The Effects of LAA Ligation on Electrical Activity. Heart Rhythm. 2014 May; 11(5):864-70.

iii Di Biase L, et al. Left atrial appendage: an underrecognized trigger site of atrial fibrillation. Circulation. 2010 Jul 13;122(2):109-18.

Related Content

Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
Cardiovascular Research Foundation (CRF) announced the promotion of Juan F. Granada, M.D., as the foundation’s president and chief executive officer (CEO). CRF sponsors TCT.

The Cardiovascular Research Foundation (CRF) announced the promotion of Juan F. Granada, M.D., as the foundation’s president and chief executive officer (CEO).

Feature | Cath Lab| September 12, 2017
September 12, 2017 – The Cardiovascular Research Foundation (CRF) a
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Siemens Healthineers Receives FDA Clearance for TrueFusion Structural Heart Disease Feature
Technology | Cardiovascular Ultrasound| September 06, 2017
The U.S. Food and Drug Administration (FDA) has cleared TrueFusion, a new cardiovascular application from Siemens...
Overlay Init